Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Standard
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. / Distler, O; Highland, KB; Gahlemann, M; Azuma, A; Fischer, A; Mayes, MD; Raghu, G; Sauter, W; Girard, M; Alves, M; Clerisme-Beaty, E; Stowasser, S; Tetzlaff, K; Investigators, SENSCIS Trial.
in: NEW ENGL J MED, 05.2019.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
AU - Distler, O
AU - Highland, KB
AU - Gahlemann, M
AU - Azuma, A
AU - Fischer, A
AU - Mayes, MD
AU - Raghu, G
AU - Sauter, W
AU - Girard, M
AU - Alves, M
AU - Clerisme-Beaty, E
AU - Stowasser, S
AU - Tetzlaff, K
AU - Investigators, SENSCIS Trial
PY - 2019/5
Y1 - 2019/5
UR - http://europepmc.org/abstract/med/31112379
U2 - 10.1056/nejmoa1903076
DO - 10.1056/nejmoa1903076
M3 - SCORING: Journal article
C2 - 31112379
JO - NEW ENGL J MED
JF - NEW ENGL J MED
SN - 0028-4793
ER -